Blue Eagle Lithium
High Times
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 10/22/2018 11:08:10 AM - Followers: 217 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

Blue Eagle Lithium
High Times
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... 10/09/2018 02:31:30 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2018 10:45:51 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2018 10:42:26 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2018 10:39:50 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2018 10:36:48 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12411  Sticky Note Vienna, VA, January 3, 2018 -- CEL-SCI Foxwoods Man 01/03/18 08:19:00 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#17128   LATEST institutional ownership. yankeesnyc27 10/22/18 11:08:09 AM
#17127   9/30/2018 Tute ownership IS NOT OUT yet. sushifishman 10/22/18 09:27:55 AM
#17126   Try this one... RobotDroid 10/22/18 09:25:09 AM
#17125   Robot THIS IS NOT A REPORT FROM 9/30/2018... sushifishman 10/22/18 09:13:56 AM
#17124   From Yahoo board and short interest list: RobotDroid 10/22/18 09:02:00 AM
#17123   It was like 6am so I didn't catch pijoe 10/21/18 07:13:34 PM
#17122   You should know me well enough to know learning curve 10/21/18 04:47:44 PM
#17121   Yes. Theses were lil bonuses given I believe. sushifishman 10/21/18 11:04:51 AM
#17120   Sushifishman, on Nasdaq.com on 09/28/18 Geert and Prichep Sanderson 10/21/18 09:41:27 AM
#17119   Haha I thought so. But alas you are pijoe 10/21/18 06:16:53 AM
#17118   Don’t think anybody is really intoxicated with the learning curve 10/21/18 02:02:26 AM
#17117   I would like to know what potential partnerships pijoe 10/20/18 01:01:23 PM
#17116   Where does short come from? Seriously... learning curve 10/20/18 01:17:05 AM
#17115   I agree completely. learning curve 10/20/18 01:07:20 AM
#17114   What 2 stocks are you referring to? learning curve 10/20/18 12:45:49 AM
#17113   I have some ideas as to why cvm learning curve 10/19/18 11:41:44 PM
#17112   Sushi: I'm glad that at least one sab63090 10/19/18 04:24:36 PM
#17111   Does 298 have anything to do with volume? yankeesnyc27 10/19/18 04:08:19 PM
#17110   No volume...its a nothingburger sushifishman 10/19/18 03:58:45 PM
#17109   Freaky Friday? sab63090 10/19/18 03:35:53 PM
#17108   Your post helped share value? yankeesnyc27 10/19/18 12:44:28 PM
#17107   Yank can sniff out a manipulator from a Trustbaby 10/19/18 12:34:35 PM
#17106   Wow, someone really gets excited. fluteman 10/19/18 12:32:28 PM
#17105   "I don't want to discuss the other stock yankeesnyc27 10/19/18 12:24:15 PM
#17104   I don't want to discuss the other stock fluteman 10/19/18 11:44:00 AM
#17103   TRVN OR CTIC???? yankeesnyc27 10/19/18 10:38:08 AM
#17102   Flute here's the issue. In your first post georgebailey 10/19/18 10:24:14 AM
#17101   I can also appreciate the paranoia of everything fluteman 10/18/18 03:40:06 PM
#17100   AND... They all took the cold fill facility yankeesnyc27 10/18/18 03:37:11 PM
#17099   Why do shorts always show up with a Trustbaby 10/18/18 03:25:23 PM
#17098   Fluteman: I certainly can understand why you sab63090 10/18/18 03:08:12 PM
#17097   I too have held shares over the long Kpauliukonis 10/18/18 02:25:27 PM
#17096   Is that the standard answer, Mr. K? fluteman 10/18/18 02:06:54 PM
#17095   Are you another shorter? What was your Kpauliukonis 10/18/18 01:45:35 PM
#17094   Is CVM possibly another CTIC? fluteman 10/18/18 12:43:22 PM
#17093   waiting for this puppy to go back to ErIsKoffie 10/18/18 09:51:54 AM
#17092   Waiting for another low to buy my other RobotDroid 10/18/18 09:04:26 AM
#17091   So LEAPS also could get this status. RobotDroid 10/17/18 12:42:04 PM
#17090   Could get fast tracked, orphan drug status, on RobotDroid 10/17/18 12:41:11 PM
#17089   Ill add some catalysts georgebailey 10/17/18 12:09:03 PM
#17088   Sushi: I see your post got duped sab63090 10/17/18 11:23:25 AM
#17087   These are the near term catalysts as I sushifishman 10/17/18 11:05:42 AM
#17086   These are the near term catalysts as I sushifishman 10/17/18 11:05:35 AM
#17085   Isn't anyone expecting (hoping for?) news on the sab63090 10/17/18 10:59:41 AM
#17084   Parker, OK. But thats not for 5-6 months. sushifishman 10/17/18 10:47:46 AM
#17083   Well my guess is that it works and PARker1703 10/17/18 10:43:42 AM
#17082   Parker, No catalyst coming for 5-6 months. What sushifishman 10/17/18 10:34:34 AM
#17081   Who in the hell would sell right now???? PARker1703 10/17/18 10:18:42 AM
#17080   CVM: A NEW SOLUTION IN HEAD & NECK CANCER RobotDroid 10/17/18 09:33:10 AM
#17079   I never ever pay to read an article, RobotDroid 10/17/18 09:29:56 AM
PostSubject